newsfilter
← Latest News
GlobeNewswire·

Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity

NEW YORK, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (NASDAQ:PBM) ("Psyence BioMed" or the "Company"), a biopharmaceutical company advancing nature-derived psilocybin and ibogaine therapies for unmet